Cardiovascular Effects of Non-Selective Monoamine Oxidase Inhibitors and Intranasal Esketamine Combination in Depression - A Quasi-Experimental Design with Bayesian Analyses.
Pharmacopsychiatry June 2, 2025 Ludovic C Dormegny-Jeanjean, Suzie Lenoir, Ilia Humbert et al. 1 citation
Ketamine and esketamine, when used alongside non-selective monoamine oxidase inhibitors, do not cause clinically significant increases in blood pressure or heart rate. In 193 esketamine sessions with 13 patients, systolic pressure rose by 8.68 mmHg, diastolic by 6.57 mmHg, and heart rate by 3.5 beats per minute—changes not considered clinically meaningful. The combination of esketamine with monoamine oxidase inhibitors was not linked to elevated blood pressure. These results suggest minimal risk of sympathomimetic synergy with this drug combination, supporting its safe use in treatment-resistant depression.